# OrphanCure Full Pipeline Report: repodb_0d57eaf7fcf55450

- Drug: Valproic Acid
- Disease: Absence Epilepsy
- Mode: full
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Valproic acid (VPA) is mechanistically linked to ALDH5A1 inhibition, which may alleviate hyperexcitability in myoclonic epilepsy. Clinical literature indicates VPA is an effective treatment for juvenile myoclonic epilepsy (JME), though its use is limited by teratogenic potential. Further investigation into VPA's efficacy and safety in specific myoclonic epilepsy subtypes is warranted.",
      "evidence_counts": {
        "total_papers": 45,
        "supporting": 16,
        "contradicting": 9,
        "inconclusive": 20
      },
      "common_targets_count": 1
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose VALPROIC ACID for myoclonic epilepsy",
      "drug": {
        "id": "CHEMBL109",
        "name": "VALPROIC ACID",
        "aliases": [
          "Valproate",
          "Depakene",
          "Depakote",
          "VPA",
          "Epilim"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "EFO_1001900",
        "name": "myoclonic epilepsy",
        "aliases": [
          "myoclonic-atonic epilepsy",
          "epilepsy, myoclonic",
          "myoclonic seizures with epilepsy",
          "epilepsia myoclonica",
          "myoclonic epilepsy syndrome"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 1,
      "mechanisms": [
        {
          "target": "ALDH5A1",
          "drug_action": "INHIBITOR",
          "disease_score": 0.065,
          "pathway": "Valproic acid inhibits ALDH5A1, an enzyme involved in the degradation of succinic semialdehyde, leading to the accumulation of GABA and potentially alleviating the hyperexcitability characteristic of myoclonic epilepsy."
        }
      ]
    },
    "4_target_overlap_summary": {
      "total_overlapping": 1,
      "top_targets": [
        {
          "symbol": "ALDH5A1",
          "name": "aldehyde dehydrogenase 5 family member A1",
          "drug_action": "INHIBITOR",
          "disease_association_score": 0.065
        }
      ]
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 45,
      "polarity": {
        "supports": 16,
        "contradicts": 9,
        "inconclusive": 20
      },
      "support_ratio": "16 of 45 retrieved papers support the hypothesis",
      "queries_used": 11,
      "top_papers": [
        {
          "pmid": "33423017",
          "title": "Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.",
          "year": "2021",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Case report limit",
            "Title Match"
          ]
        },
        {
          "pmid": "34817852",
          "title": "Topiramate for juvenile myoclonic epilepsy.",
          "year": "2021",
          "relevance_score": 8.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "39703113",
          "title": "Causal Relationships Between Epilepsy, Anti-Epileptic Drugs, and Serum Vitamin D and Vitamin D Binding Protein: A Bidirectional and Drug Target Mendelian Randomization Study.",
          "year": "2024",
          "relevance_score": 7.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Targets: 1",
            "Recent"
          ]
        },
        {
          "pmid": "37267668",
          "title": "Diagnosis and treatment of late-onset myoclonic epilepsy in Down syndrome (LOMEDS): A systematic review with individual patients' data analysis.",
          "year": "2023",
          "relevance_score": 7.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "38117708",
          "title": "[Reflex triggers in juvenile myoclonic epilepsy].",
          "year": "2023",
          "relevance_score": 7.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "37378757",
          "title": "Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.",
          "year": "2023",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "30687937",
          "title": "Topiramate for juvenile myoclonic epilepsy.",
          "year": "2019",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "28434203",
          "title": "Topiramate monotherapy for juvenile myoclonic epilepsy.",
          "year": "2017",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "38461125",
          "title": "Drug-resistant juvenile myoclonic epilepsy: A literature review.",
          "year": "2024",
          "relevance_score": 7.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "26695884",
          "title": "Topiramate monotherapy for juvenile myoclonic epilepsy.",
          "year": "2015",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "Medium",
        "literature_strength": "High",
        "clinical_evidence": "Medium"
      },
      "quality_scorecard": {
        "overall_score": 0.912,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "1/1 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "1 verified, 0 partial out of 1"
          },
          "mechanistic_specificity": {
            "score": 1.0,
            "reason": "1/1 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "1/1 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Teratogenic potential of valproic acid."
      ],
      "limitations": [
        "The provided literature primarily focuses on Juvenile Myoclonic Epilepsy (JME) and does not extensively cover other forms of myoclonic epilepsy.",
        "The mechanistic data is limited to a single target (ALDH5A1) and does not provide a comprehensive view of valproic acid's interactions.",
        "The majority of the retrieved papers discuss valproic acid as a historical or comparative treatment, rather than a primary focus for repurposing."
      ],
      "missing_data": [
        "Direct studies on valproic acid's efficacy in non-JME myoclonic epilepsy subtypes.",
        "Detailed comparative studies on valproic acid versus newer AEDs specifically for myoclonic epilepsy, beyond JME.",
        "Studies exploring the precise downstream effects of ALDH5A1 inhibition by valproic acid in the context of myoclonic epilepsy."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Evaluate the efficacy of valproic acid in specific subtypes of myoclonic epilepsy beyond JME.",
        "Assess the risk-benefit profile of valproic acid in patient populations where teratogenicity is not a concern.",
        "Investigate alternative AEDs for JME in women of childbearing age, as indicated by current clinical practice."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 1,
      "claims": [
        {
          "claim_id": "CLM-5e999e",
          "statement": "Valproic acid inhibits ALDH5A1, an enzyme involved in GABA metabolism, potentially reducing hyperexcitability in myoclonic epilepsy.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [
            "ALDH5A1"
          ],
          "citation_count": 1,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 1,
      "entries": [
        {
          "claim_id": "CLM-5e999e",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "56e762a00c34",
          "timestamp": "2026-06-03T11:45:44.243238+00:00",
          "paper_evidence": [
            {
              "pmid": "33423017",
              "snippet": "Valproic acid (VPA) is the most effective medication in juvenile myoclonic epilepsy (JME) but, due to its teratogenic potential, levetiracetam (LEV) and lamotrigine (LTG) are preferred in women of chi",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [
            {
              "target": "ALDH5A1",
              "action": "INHIBITOR"
            }
          ],
          "queries_used_count": 11
        }
      ]
    }
  },
  "metadata": {
    "run_id": "56e762a00c34",
    "created_at": "2026-06-03T11:45:22.818293+00:00",
    "drug": "VALPROIC ACID",
    "disease": "myoclonic epilepsy",
    "total_claims": 1,
    "quality_score": 0.9125,
    "reruns": 0
  }
}
```
